IDEXX Laboratories, Inc. $IDXX Shares Sold by UNIVEST FINANCIAL Corp

UNIVEST FINANCIAL Corp cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 40.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,880 shares of the company’s stock after selling 4,666 shares during the quarter. UNIVEST FINANCIAL Corp’s holdings in IDEXX Laboratories were worth $4,396,000 as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. Empowered Funds LLC lifted its holdings in shares of IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new position in IDEXX Laboratories during the 2nd quarter worth $265,000. Park Avenue Securities LLC raised its position in IDEXX Laboratories by 9.1% during the 2nd quarter. Park Avenue Securities LLC now owns 2,470 shares of the company’s stock worth $1,325,000 after buying an additional 206 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $29,000. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of IDEXX Laboratories by 3.9% in the second quarter. Public Employees Retirement System of Ohio now owns 27,716 shares of the company’s stock valued at $14,865,000 after acquiring an additional 1,041 shares in the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.98% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. BTIG Research increased their price target on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 target price on IDEXX Laboratories in a research note on Monday, November 3rd. Barclays assumed coverage on IDEXX Laboratories in a report on Monday, December 8th. They issued an “overweight” rating and a $850.00 price target for the company. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 17th. Finally, UBS Group increased their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Price Performance

IDXX stock opened at $691.05 on Friday. The stock’s 50 day moving average price is $705.75 and its 200 day moving average price is $653.69. The firm has a market cap of $55.18 billion, a P/E ratio of 54.80, a PEG ratio of 3.72 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 0.87 and a current ratio of 1.18. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The business’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. On average, sell-side analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.